Clinical Trial Search block Test

001 Healthy Kids Demo Trial 02

001 Healthy Kids Demo Trial 01

  • Condition(s): Bones and Joints, Kaposi's Sarcoma, Leukemia, other, Anus
  • Phase: II/III

What is the goal of the study?

To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of 9-ING-41 as a single agent and in combination with Irinotecan in pediatric patients with refractory malignancies. 2. To describe the toxicity profile and DLT of 9-ING-41 as a single agent and in combination with Irinotecan in pediatric patients with refractory malignancies. 3. To characterize the pharmacokinetics of 9-ING-41 as a single agent and in combination with Irinotecan when administered to pediatric patients with refractory malignancie

Who can participate in the study?

Everyone

Study Team: